HLA基因多态性与药物性肝损伤的关系  

Association between human leukocyte antigen gene polymorphism and drug-induced liver injury

作　　者：王露媛 姜敏杰 高普均[1] WANG Luyuan;JIANG Minjie;GAO Pujun(Department of Hepatology,The First Hospital of Jilin University,Changchun 130021,China)

机构地区：[1]吉林大学第一医院肝胆胰内科,长春130021

出　　处：《临床肝胆病杂志》2021年第2期475-479,共5页Journal of Clinical Hepatology

基　　金：“艾滋病和病毒性肝炎等重大传染病防治”国家科技重大专项(2017ZX10202202,2018ZX10302206,2018ZX10723203);国家重点研发计划“精准医学研究”专项(2017YFC0908103);吉林省自然科学基金(2018SCZWSZX-003,JLSCZD2019-008);吉林大学高层次创新团队建设项目(2017TD-08);中央高校基本科研业务费专项资金。

摘　　要：药物性肝损伤是临床常见的药物不良反应之一,其临床诊治极为困难,且易发展成急性肝衰竭。相关药物基因组学研究已发现人类白细胞抗原(HLA)基因与药物性肝损伤之间有很强的遗传相关性。综述了药物性肝损伤的HLA基因多态性研究进展,以期揭示免疫因素在药物性肝损伤发生机制中的作用,发现相应基因生物标志物,提高临床用药的安全性。Drug-induced liver injury(DILI)is one of the common adverse drug reactions in clinical practice,and it is difficult to diagnose and treat and may easily develop into acute liver failure.Related pharmacogenomics studies have found a strong genetic correlation between human leukocyte antigen(HLA)genes and DILI.This article reviews the research advances in HLA gene polymorphism in DILI,in order to reveal the role of immune factors in the pathogenesis of DILI,identify related genetic biomarkers,and improve the safety of clinical medication.

关 键 词：化学性与药物性肝损伤 HLA抗原 多态性 单核苷酸 

分 类 号：R575[医药卫生—消化系统]